article · Asian Pacific Journal of Cancer Biology
Background: Prostate cancer is the second most common malignancy affecting males. TROP2 is a cell surface marker of embryonic stem cells that has been implicated in development of many cancers. Objective: This study aimed to investigate the immunohistochemical expression of TROP2 Protein in PCa and BPH tissues and explore TROP2 association with the histopathological parameters of PCa. Materials and Methods: a cross-sectional analytical study was conducted in the pathology laboratory of Suez Canal University Hospital on thirty PCa and fifteen BPH specimens (n=45). Sample was collected from the archived blocks of BPH and prostatic carcinoma. TROP2 expression was assessed using immunohistochemistry. Results: TROP2 showed positive membranous staining in prostatic epithelial cells of 100% of PCa & in eleven out of fifteen BPH specimens and the difference between the two groups was statistically significant (p-value >0.001). Moreover, high TROP2 expression was found in nineteen PCa and in only four BPH specimens and the difference between the two groups regarding TROP2 staining intensity was also statistically significant (p-value= 0.005). TROP2 showed positive expression in 100% of specimens showing positive perineural invasion and a statistically significant association was found between both TROP2 staining intensity and perineural invasion (p-value >0.05). In addition, TROP2 showed statistically significant validity in discriminating between PCa and BPH (p-value <0.001). Conclusions: TROP2 is a sensitive prostatic immunohistochemical marker and its expression in PCa is higher than that in BPH. TROP2 is associated with poor prognostic factors of PCa as perineural invasion.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.31557/apjcb.2026.11.2.451-457
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.